Cancer of Unknown Primary
8 clinical trials · Condition
◉ Watch Cancer of Unknown Primary
| Record | Firm | Date |
|---|---|---|
| Phase II Trial of Lu-177 FAP-2286 in Patients With Carcinoma of Unknown Primary (NCT07434180) | Peter MacCallum Cancer Centre, Australia | 2026-06-01 |
| Pucotenlimab Combined with MRG002 for HER2-positive Cancer of Unknown Primary (NCT06869174) | Zhiguo Luo, MD, PhD | 2025-03-08 |
| Enabling Genomic Testing in Cancer of Unknown Primary (NCT06695494) | The Christie NHS Foundation Trust | 2024-08-15 |
| [18F]F-FAPI PET-CT to Identify Carcinoma of Unknown Primary Origin (NCT06644716) | Erasmus Medical Center | 2024-07-19 |
| Agnostic Therapy in Rare Solid Tumors (NCT06638931) | Instituto do Cancer do Estado de São Paulo | 2024-07-16 |
| Tislelizumab Combined With Chemotherapy in the Treatment of Bone Metastases of Unknown Primary (NCT05241132) | Wei Xu | 2021-11-12 |
| PD-1 Inhibitor and Nab-paclitaxel and Bevacizumab in CUP (NCT04848597) | Fudan University | 2021-05-13 |
| Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors (NCT02897375) | Emory University | 2016-10-24 |
Track Cancer of Unknown Primary automatically
Every clearance here is in the API, with alerts when new ones post.